共 113 条
[11]
Padrik P(2014)Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish renal Cancer group (DARENCA) study-2 Eur J Cancer 50 553-562
[12]
Aareleid T(2013)Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008) Br J Cancer 108 1541-1549
[13]
Motzer RJ(2017)Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study Onco Targets Ther 10 371-385
[14]
Hutson TE(2012)Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database Med Oncol 29 3314-3320
[15]
Tomczak P(2016)Variation in use of targeted therapies for metastatic renal cell carcinoma: results from a Dutch population-based registry BMC Cancer 16 364-1297
[16]
Michaelson MD(2019)Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis Cancer Manag Res 11 1289-927
[17]
Bukowski RM(2016)Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Lancet Oncol 17 917-1813
[18]
Oudard S(2015)Nivolumab versus Everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1290
[19]
Motzer RJ(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-undefined
[20]
Hutson TE(undefined)undefined undefined undefined undefined-undefined